EXEL News and Press, Exelixis Inc. From 12/03/22

High conviction. That's what you want to have with the stocks you buy. Such stocks are ones that you can be enthusiastic about -- and buy heavily. We asked three Motley Fool contributors to identify stocks for which they have high convictions about buying right now. Here's why they think that...

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am P...

In seeking the best stocks in healthcare or cannabis under $20, I look for companies that have consistent revenue growth and a business where there's still plenty of untapped potential, considering long-term trends. Two that stand out in these categories now are biotech company Exelix...

— Presentations to be webcast on www.exelixis.com — Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November: Stifel...

As Thanksgiving approaches, 2022 is coming to a close -- and what a year the stock market had. The S&P 500 is still down 21% year to date. Most growth stocks have taken a beating this year. But amid this downfall, some companies still shone, giving investors a glimpse of hope. O...

Summary Today, we circle back on mid-cap oncology concern Exelixis, Inc. which just delivered another quarter of rock-solid results. Its blockbuster drug CABOMETYX continues to show good growth and the company is sitting on a massive cash hoard. What is the best way to trade t...

— New priority discovery programs focused on three oncology targets with potential to develop antibody-drug conjugates (ADCs) for a variety of solid tumor indications — Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announce...

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q3 2022 Earnings Call Nov 01, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q3 2022 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Se...

Exelixis ( NASDAQ: EXEL ) has brokered collaboration deals with two companies giving the biotech the right to acquire a potential first-in-class peptide-drug conjugate and work on the development of an antibody targeting SIRPα. In its deal with Cybrexa Therapeutics ...